PerkinElmer last week has appointed Richard Begley vice president and general manager of its Analytical Sciences business.
In this position, Begley will “develop and lead the growth strategy” globally for the firm’s entire portfolio of analytical instrumentation, which includes chromatography, atomic and molecular spectroscopy, thermal analysis, and laboratory information management systems.
Begley joins PerkinElmer from Ensemble Discovery, where he was president and CEO. Before this he was CEO and president of 454 Life Sciences.
Former Applied Biosystems President Cathy Burzik has been named to the board of directors at Bausch & Lomb.
Burzik left ABI in October 2006 to become CEO at the medical company Kinetic.
Robert Ellis has been elected to the board of directors at SciGene, the company said this week. Ellis is currently executive chairman of Biotrove, where he was formerly CEO and president.
Ellis also was vice president of R&D at Affymetrix and was a senior manager at Genometrix, Applied Biosystems, PerkinElmer and Hewlett Packard.
MDS this week said it has promoted Douglas Prince to be its new CFO and executive vice president of finance.
Prince recently was involved in risk management and internal auditing at PerkinElmer, where he also served as vice president and CFO. Prince also worked in the financial departments at General Electric and at AlliedSignal.
BioMicro Systems has named Rob Parry vice president of manufacturing, the company said last week.
In the position, Parry will be responsible for expanding manufacturing capacity for the company’s hybridization system products.
Parry formerly worked in manufacturing at Nanosys; was vice president of manufacturing at Fluidigm; and worked in Agilent Technologies’ microarray business.
William Clarke has been named to Caden Biosciences’ board of directors, the company said this week.
Clarke is CEO of Cellectar, and recently was executive vice president and chief technology officer and chief medical officer at GE Healthcare.
Prior to that, Clarke also was a vice president at Amersham Health and was a director of biological sciences at Glaxo Wellcome UK.
CombiMatrix Molecular Diagnostics last week said CEO Matt Watson will step down and will be replaced by Mansoor Mohammed, who is currently president and COO. Watson will stay on with the company for three months as a consultant.